Background. It is not clear whether renal allograft removal affects the outcome of renal retransplantation. This study aimed to determine the effect of allograft nephrectomy (AN) and no-AN (No AN) on renal retransplantation. Methods. A systematic review and meta-analysis were conducted using MEDLINE, Embase and the Cochrane Library. Observational studies or randomized controlled trials including renal retransplantation recipients with AN or No-AN were included. The primary outcomes were graft survival, patient survival, acute rejection (AR) and delayed graft dysfunction; the secondary outcomes were positive panel reactive antibody rate and serum creatinine level at 1 year after retransplantation, cold ischemia time and time of hemodialysis before recent transplantation. Pooled estimates of odds ratios (ORs) and the weighted mean difference for outcomes were calculated. 
I N T R O D U C T I O N
In the past few decades there have been great advances in all aspects of renal transplantation, resulting in a significant increase in renal allograft survival. As the rate of transplant failure remains about 10% in the first year and then increases 3-5% every year, an increasing number of transplant failure patients will become potential candidates for retransplantation. The overall survival of patients with failed renal allografts will be improved after retransplantation [1] . Several studies have focused on the influence of primary allograft nephrectomy (AN) on retransplantation outcome [2, 3] . Meanwhile, it is not clear whether renal allograft removal affects the long-term outcome of renal retransplantation. We conducted a systematic review and meta-analysis to assess the effects of graft nephrectomy on renal retransplantation.
M A T E R I A L S A N D M E T H O D S

Types of studies, participants and interventions
Randomized controlled trials were first included in this systematic review and meta-analysis, followed by applicable nonrandomized studies when necessary (e.g. prospective and retrospective longitudinal cohort studies). We selected articles published in English from the electronic databases listed under Search strategy, but we referred to the abstracts of non-English articles in order to evaluate the same results as those from English articles. The analysis included participants who had failure of the renal allograft, including unexplained fever, graft pain or tenderness, persistent hematuria, graft infection, uncontrolled hypertension or an asymptomatic nonfunctioning renal allograft among secondary or multiple renal transplant recipients with or without a previous graft nephrectomy. Postoperative follow-up duration was >1 year. Some reports were excluded from this meta-analysis, including first and second transplant comparative studies and combined organ transplantation studies. Duplicate reports from the same patient group, center or author or those with considerable overlaps with previously assessed cohorts were not included in the metaanalysis. Abstracts, case reports, letters, editorials, observational reviews, other noncomparative studies and expert opinions were also excluded.
Types of outcome measures
Primary outcomes included graft survival, patient survival, acute rejection (AR), delayed graft dysfunction (DGF), positive panel reactive antibody (PRA) rate and serum creatinine (SCr) level at 1 year after retransplantation. Secondary outcomes were cold ischemia time and time of hemodialysis before recent transplantation. AR was identified clinically by the presence of fever and a tender and swollen graft, with an increasing SCr level, combined with a renal biopsy (except if contraindicated) analyzed according to the Banff classification. DGF was described as the postoperative need for dialysis in the first posttransplant week.
Search strategy
We searched MEDLINE (PubMed), Embase and the Cochrane Library for relevant studies from January 1990 to June 2017. The search strategy for MEDLINE was based on Medical Subject Heading terms and text words of the key article. Search keywords included 'renal retransplantation', 'multiple renal transplantation', 'allograft failure', 'graft nephrectomy', 'patient and graft survival' and their combinations (Supplementary data, Table S1 ). We examined the list of references for all (and their related) articles to identify missing articles. We also searched the clinical trials website (ClinicalTrials.gov) to identify unpublished research up to 20 January 2017 that could be relevant to our review.
A flow diagram outlining the study selection process is depicted in Figure 1 .
Data extraction and quality assessment
Two independent reviewers (J.L.W. and J.C.H.) scanned the title and abstract of the articles. They also reviewed full articles to assess whether they were eligible for inclusion. Standardized forms were developed for data extraction. Reviewers extracted information on study characteristics, study participants, eligibility criteria, intervention components, outcome measures, and methods of ascertaining outcomes. Extraction data from each article were subsequently double-reviewed. The second reviewer confirmed the completeness and accuracy of the first reviewer's data. Inconsistencies were resolved by discussion or consultation with the third researcher (Y.X.).
Assessment of risk for bias in included studies
The Newcastle Ottawa scale was independently applied by two authors to assess the quality of analysis. The scale criteria included patient selection, comparability between the groups and outcome evaluation. The score of each study was ranked on a scale of zero to nine (as stars). The maximum number of stars for the category of patient selection, comparability and outcome was three, four and two, respectively. A study scoring at least six stars was considered to be of high quality. Funnel plot analysis and Begg's and Egger's tests were used to assess for publication bias in all comparative models. If publication bias was identified, a nonparametric trim-and-fill method was applied to adjust for the publication bias.
Measures of treatment effect
We summarized descriptive statistics for demographic data. The AN intervention data were pooled to estimate all outcomes. The primary and secondary outcomes were reported as the odds ratio (OR) with 95% confidence interval (CI), as calculated using Stata 12.0 software (StataCorp, College Station, TX, USA). A P-value 0.05 was considered statistically significant.
Assessment of heterogeneity
Heterogeneity was assessed using the Higgins chi-square test. If P > 0.1 or I 2 < 50%, heterogeneity was considered to be within an appropriate range and data were pooled using a fixed effects model. Otherwise, if P < 0.1 or I 2 > 50%, poor homogeneity was present and a random effects model was applied. The degree of clinical heterogeneity was analyzed based on the transplantation era, immunosuppressant regimen, type of study and length of follow-up between the AN group and No-AN group.
Data synthesis
Stata 12.0 was used for the meta-analysis. The weighted mean difference was used to analyze continuous variables and dichotomous variables were analyzed by using OR and 95% CI.
Sensitivity analysis
A sensitivity analysis was performed to test the impact of each study by removing each study from the analysis separately and recalculating the pooled estimates.
R E S U L T S
Literature search and study characteristics
We identified 260 potentially relevant clinical studies, of which 27 full articles were retrieved. Fourteen of these 27 articles were excluded, including four articles describing studies with insufficient follow-up time, six articles for reporting insufficient data, one article describing a meta-analysis, one article reporting a study that included only the No-AN group and three articles reporting incomplete data ( Figure 1 ). There were no randomized controlled trials reporting on a direct comparison of AN versus No-AN among the retrieved articles. All studies were clinically controlled trials. The characteristics of the 13 articles that fulfilled the inclusion criteria are shown in Table 1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . There are 20 studies included in those 13 articles, including a total of 1802 patients, of which 919 (51.0%) underwent AN and 883 (49.0%) had not undergone AN.
Meta-analysis: effect of AN versus No-AN on renal transplantation
The pooled effect of outcome were shown in Table 2 and the forest plots were shown in Figure 2 and Supplementary data, Figure S1 .
Sensitivity analysis. According to the modified Newcastle Ottawa scale, 17 high-quality studies scored at least six stars and were selected for sensitivity analysis. Results indicated that there was no significant difference compared with the holistic analysis, as shown in Figure 3 and Supplementary data, Figure S2 .
Heterogeneity. Studies included in our analysis were clinically heterogeneous in terms of transplantation era, immunosuppressant regimen, type of study and length of follow-up, cause of primary failed graft nephrectomy, method of detecting PRA and immunosuppressant withdrawal protocols. Mild to moderate (I 2 < 50%) statistical heterogeneity was also noted in various outcomes. Because of the limited number of studies and insufficient clinical data, it was difficult to perform the supernumerary subgroup analysis in accordance with the original plans. The sensitivity analysis showed no significant differences in the pooled estimate when studies were omitted from the analysis.
Publication bias. Funnel plots calculated based on the outcomes are shown in Figure 4 and showed no publication bias in our meta-analysis. The Begg's and Egger's tests were subsequently performed to provide statistical evidence regarding the symmetry of funnel plots. There was also no evidence of publication bias in terms of 1-year graft survival rate (P ¼ 1.000 and P ¼ 0.307), 3-year graft survival rate (P ¼ 0.06 and P ¼ 0.46), 5-year graft survival rate (P ¼ 0.62 and P ¼ 0.95), rate of AR (P ¼ 0.35 and P ¼ 0.60), SCr level (P ¼ 0.13 and P ¼ 0.14), cold ischemic time (P ¼ 0.76 and P ¼ 0.76) and rate of DGF (P ¼ 0.62 and P ¼ 0.60) (Supplementary data, Table S2 ). There was no need to correct for possible publication bias by the trimand-fill method.
D I S C U S S I O N
In recent decades, an increasing number of patients have returned to dialysis following transplant failure. Retransplantation has been demonstrated to improve the overall survival rate of patients in those cases [1] . The incidence of retransplantation on the waiting list varied from 5 to 13.7% in different countries [15, 16] . Several factors were found that could influence retransplantation outcome, including human leukocyte antigen (HLA) mismatch, flow cytometric cross-matching, failed graft nephrectomy, survival duration of the primary graft, Ahmad et al.
[ age of the recipient and donor and peak PRA [17, 18] . Although several studies have investigated the effect of graft nephrectomy failure on retransplantation outcome, the role of graft nephrectomy remains controversial. Thus the rate of AN performed prior to retransplantation varies greatly from 0.5 to 43%, depending on the protocol of the individual center [3, 5, 19] . In some transplant centers, the indications for AN were pain, anemia, recurrent urinary tract infections, hematuria or the need to create space for the new graft. However, some clinicians questioned this decision. They believed that even apparently asymptomatic patients may have suffered a chronic inflammatory response and thus nephrectomy should be done to avoid the risk of its consequences [20] . In our meta-analysis, most of the patients underwent nephrectomy because of symptoms, while some did not. When considering prophylactic nephrectomy, increased antibody sensitization has become one of the greatest barriers to retransplantation in modern times. The immunologic effect of graft nephrectomy was previously observed, as demonstrated by elevated PRA levels in patients following AN, which may be detrimental for the new transplant [4, 7] . Some studies reported only a transient effect on PRA levels after transplant nephrectomy [21] . Douzdjian et al. [6] found that higher preformed antibody levels were not influenced by nephrectomy in 127 retransplant patients. Our meta-analysis showed significantly higher levels of PRA before retransplantation in the AN group compared with the No-AN group. Possible causes are cessation of immunosuppression giving rise to antibody production; the transplantectomy itself, which inhibits antibody absorption of the graft; and the persistence of donor antigen-presenting cells after transplantectomy [22, 23] . PRA levels might be reduced due to prolonged immunosuppressant treatment after renal allograft failure without nephrectomy [24, 25] .
An increasing number of studies have shown that donorspecific antibodies (DSAs) are one of the important immune factors that affect transplant outcome. Calcineurin inhibitor minimization or withdrawal strategies may increase the incidence of de novo DSAs and antibody-mediated rejection [26] . Del Bello et al. [23] reported independent predictive factors for developing DSAs after losing the kidney allograft and stopping immunosuppressants were AN and the number of HLA mismatches at transplantation. Preexisting antibodies or developing DSAs following renal transplantation are an important cause of AR, particularly if these are donor specific. Others have also shown a strong association between anti-HLA DSAs and the development of chronic rejection. Dunn et al. [27] found that PRA was one of the risk factors for cell-mediated rejection in multivariate analyses including 587 kidney transplants. The rate of AR and DGF in our meta-analysis was higher in the AN group than the No-AN group (31.4 and 24.7%; 32.3 and 26.5%, respectively), a finding that is aligned with previous reports [28] [29] [30] . Although DSAs are important risk factors for graft loss, the majority of patients with DSAs have stable allograft function and experience no rejection [31] . It is therefore important to determine the pathogenic role and specificity of anti-HLA classes I and II and non-HLA DSAs, and to better understand the effect of de novo DSAs compared with preexisting DSAs.
On the other hand, we also observed that cold ischemia time as a nonimmunological factor was longer in the AN group. Injuries induced by cold ischemia generate inflammatory and immune responses that may potentially result in delayed graft function [32] . In addition, persistent BK viremia does not negatively affect intermediate-term patient or allograft survival but is associated with an increased risk for de novo DSAs, although the exact mechanism is unclear [33] . Long-term outcome of transplantation would be influenced by the viral status of the patient. In accordance with de novo DSAs, viral status-associated nephropathy was not described in the selected literature.
We found that 3-and 5-year graft survival rates were lower in the AN group. Sumrani et al. [4] reported that nephrectomy of the primary graft was associated with a worse outcome after retransplantation. Schleicher et al. [8] reported failed allograft nephrectomy was not beneficial in terms of retransplant outcome in their series that found the mean overall graft survival time was 81.9 6 4.5 months in the AN group and 98.9 6 5.7 months in the No-AN group (P ¼ 0.03). This might be explained by elevated levels of PRA antibodies after graft nephrectomy. Interestingly, higher 5-year patient survival rates were observed in the AN group, with only five studies reporting a similar outcome, and younger patients were included, which may have contributed to this result. Tittelbach-Helmrich et al. The point estimate of the OR and WMD was considered statistically significant at the level of P < 0.05 if the 95% CI did not include the value one. If I 2 < 50% and P > 0.1, it may be considered to indicate no significant heterogeneity. WMD, weighted mean difference.
[13] also suggested transplant nephrectomy was associated with significantly longer patient survival. They found that ageadjusted patient survival at 5 years was 86.3 versus 75.4% in the AN and No-AN groups, respectively (P < 0.01). However, Sanchez-Gonzalez et al. [14] found no differences in terms of AN and No-AN groups in our meta-analysis. Lair et al. [7] analyzed the effect of the presence of a primary graft on the outcome of a second graft in a rodent allograft model and in a cohort of 240 human second-kidney allograft recipients. Their study revealed no significant differences in graft outcome after a second transplant with or without primary AN. The SCr level is an important indicator for monitoring renal function and has been widely applied to clinical work [34, 35] . Our study found no significant difference in SCr levels between the two groups, which showed similar 1-year graft survival rates. AN before renal retransplantation would seem to have no significant advantages in improving the function of further grafts within 12 months. We hypothesized that there was no difference in 1-year graft survival rates between the AN and No-AN groups because of more aggressive immunosuppressive therapy early on after retransplantation. With time after transplantation, higher levels of de novo antibodies may result in a decline in 3-and 5-year survival rates in the AN group. More studies with longer follow-up after retransplantation need to be included in future research to observe the effect.
Several trials have shown that the timing of nephrectomy in relation to retransplantation is an important determinant for new graft outcome [19] . An immunosuppressed patient who is uremic often has comorbid diseases that could additionally increase the risk for severe vascular complications such as arteriosclerosis and diabetes. Some experts also suggest significant vascular injury may occur during transplant nephrectomy. This will make retransplantation more difficult through increasing surgical complexity and the likelihood of postoperative complications [36] . Eng et al. [37] pointed out an advantage of not removing the allograft, thereby avoiding the considerable high risk for surgical morbidity and mortality.
It is understandable that there was a big difference in clinical data among the included studies from different countries and involving different age groups and ethnicities. Although there was no significant difference in baseline characteristics among the study groups, there was mild to moderate clinical heterogeneity resulting from the difference in immunosuppressive regimens used, the causes of primary failed graft nephrectomy, the method of detecting PRA and the difference in immunosuppressant withdrawal protocols. Despite the lack of sufficient data to conduct a further subgroup analysis to clarify the sources of heterogeneity, we found that each study that was ruled out separately did not have an obvious influence on the pooled results in our sensitivity analysis. Furthermore, the Begg's and Egger's tests did not show any evidence of publication bias on the total outcome, ensuring the credibility of our meta-analysis. Additionally, a number of studies reported the value of reporting results in a range rather than a standard deviation, which heightened the concerns on publication bias. A novel approach to evaluating standard deviations was reported by Hozo et al. [38] . According to the group's formula, we can use clinical trials even when all the information is not available and/or reported. In our meta-analysis, only a small number of studies with range values reported without the standard deviation were included in the data set.
There were some limitations in this meta-analysis. First, some of the included studies had a small sample size. Second, only articles published in English were included. Publication bias should be considered when the results are interpreted, despite the fact that statistical publication bias was not identified. Third, the inclusion of controlled clinical trials may lead to bias, supporting the use of more randomized controlled trial data for a more rigorous methodology. Lastly, heterogeneity on some outcomes may have affected our meta-analysis results.
In conclusion, we recommend allowing the failed graft to remain, unless symptoms dictate the need for surgery. Removal of the primary graft kidney did increase the risk for recipient sensitization. Leaving the primary asymptomatic renal graft in situ has a favorable effect on the outcomes of retransplantion. Meanwhile, we suggest DSA dynamic monitoring and better HLA matching for improved long-term outcome of retransplantation. 
A U T H O R S ' C O N T R I B U T I O N S
A C K N O W L E D G E M E N T S
The authors would like to thank H.H. Wang and B. Liu for their invaluable assistance.
F U N D I N G
This research was supported by funding from the National Natural Science Foundation of China (81370851).
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online.
C O N F L I C T O F I N T E R E S T S T A T E M E N T
The authors have no conflicts of interest to declare. The results presented in this article have not been published previously in whole or part, except in abstract form. 
